Inhibition of AMPK and BET synergistically suppresses leukemogenesis, BET recruitment, and leukemic gene expression. (A) A survival curve of mice transplanted with MLL-AF9 transformed AML cells with the indicated genotypes (n = 8). (B-C) Flow cytometry analysis of moribund mice with the indicated genotypes to detect GFP⁺ AML cells in the peripheral blood (B) and L-GMPs in the bone marrow (C) (n = 3). (D) A survival curve of mice transplanted with WT or AMPK KO AML cells that were then treated with or without JQ1 (n = 10). (E-F) Flow cytometry analysis of moribund mice with the indicated genotypes and treatments to detect GFP⁺ AML cells in the peripheral blood (E) and L-GMPs (F) in the bone marrow (n = 3). (G) Quantitative PCR with L-GMPs isolated from recipient mice transplanted with WT or AMPK KO AML then treated with or without JQ1 (n = 3). (H) ChIP-quantitative polymerase chain reaction analysis using AML cells treated with or without JQ1 to detect BRD4 occupancy at the promoter regions of Meis1 and Hoxa9, and the enhancer elements of Myc and Meis1 (n = 3). All data represent mean ± standard deviation. *P < .05; **P < .01; ***P < .001 by 1-way ANOVA, except for comparison of the survival curves in which the significance was accessed by a log-rank test.